Summary
Becton, Dickinson and Company (BD) announced the appointment of Claire Pomeroy to its Board of Directors, effective March 24, 2014. Dr. Pomeroy, who has been deemed independent by the company and the NYSE, will serve on both the Corporate Governance and Nominating Committee and the Science, Marketing, Innovation and Technology Committee. This addition to the board signifies a focus on governance, innovation, and strategic direction. In connection with her appointment, Dr. Pomeroy received a grant of 1,299 restricted stock units. This aligns her compensation with the company's long-term performance and shareholder value. Investors should view this as a positive step towards strengthening the board's expertise and oversight, particularly in areas critical to BD's future growth and market position.
Key Highlights
- 1Claire Pomeroy elected to Becton Dickinson and Company's Board of Directors.
- 2Dr. Pomeroy appointed to the Corporate Governance and Nominating Committee.
- 3Dr. Pomeroy appointed to the Science, Marketing, Innovation and Technology Committee.
- 4Dr. Pomeroy has been determined to be independent by NYSE and BD's Corporate Governance Principles.
- 5Dr. Pomeroy received a grant of 1,299 restricted stock units.
- 6The restricted stock unit grant is prorated from her election date to the 2015 Annual Meeting of Shareholders.